Sign In
Buy DARE
$2.05
-0.0900 (-4.21%)
At Close: Jun 03, 2026
Daré Bioscience to Host Second Quarter 2023 Financial Results and Company Update Conference Call and Webcast on August 10, 2023
08:00am, Thursday, 03'rd Aug 2023
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30
Daré Bioscience's 'female Viagra' could be first-in-category product: broker
04:26pm, Thursday, 13'th Jul 2023
Daré Bioscience could have a first-in-category product on its hands with its “female Viagra” offering, analysts at Dawson James believe. The women's health-focused biopharmaceutical company on Tu
Daré Bioscience to Present at the 9th Annual International Symposium of Drug Delivery Systems
05:30pm, Tuesday, 11'th Jul 2023
SAN DIEGO, July 11, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that the company's Chief Scientific Officer, David Friend, Ph
Daré Bioscience, Inc. (DARE) Q1 2023 Earnings Call Transcript
10:10pm, Thursday, 11'th May 2023
Daré Bioscience, Inc. (NASDAQ:DARE ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Sabrina Martucci Johnson – President and Chief Executive Officer John Fair – Chi
Daré Bioscience to Host First Quarter 2023 Financial Results and Company Update Conference Call and Webcast on May 11, 2023
08:00am, Thursday, 04'th May 2023
SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p
Dare Bioscience, Inc. (DARE) Q4 2022 Earnings Call Transcript
11:16pm, Thursday, 30'th Mar 2023
Dare Bioscience, Inc. (NASDAQ:DARE ) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Sabrina Johnson - President & Chief Executive Officer Lisa Walters-Hoffert - Chief
Daré Bioscience to Host Full-year 2022 Financial Results and Company Update Conference Call and Webcast on March 30, 2023
08:00am, Thursday, 23'rd Mar 2023
SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30
Daré Bioscience to Present at the 35th Annual Roth Conference
08:00am, Wednesday, 01'st Mar 2023
SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, the company's President and C
All You Need to Know About Dare Bioscience, Inc. (DARE) Rating Upgrade to Strong Buy
01:33pm, Monday, 09'th Jan 2023
Dare Bioscience, Inc. (DARE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Dare Bioscience, Inc. (DARE) Upgraded to Buy: What Does It Mean for the Stock?
05:00pm, Tuesday, 15'th Nov 2022 Zacks Investment Research
Dare Bioscience, Inc. (DARE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Dare Bioscience, Inc. (DARE) Upgraded to Buy: What Does It Mean for the Stock?
01:33pm, Tuesday, 15'th Nov 2022
Dare Bioscience, Inc. (DARE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Dare Bioscience, Inc. (DARE) Q3 2022 Earnings Call Transcript
08:45pm, Thursday, 10'th Nov 2022
Dare Bioscience, Inc. (NASDAQ:DARE ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Sabrina Johnson - President and Chief Executive Officer Lisa Walters-Hoffert - C
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Misses Revenue Estimates
12:05pm, Thursday, 10'th Nov 2022 Zacks Investment Research
Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 27.27% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock
Daré Bioscience Reports Third Quarter 2022 Financial Results and Provides a Company Update
10:45am, Thursday, 10'th Nov 2022 GlobeNewswire Inc.
Conference Call and Webcast Today at 4:30 p.m. ET
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Misses Revenue Estimates
08:17am, Thursday, 10'th Nov 2022
Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 27.27% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock
